Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 189 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France February 20, 2024 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... August 14, 2023 Breaking the silence: when cancer steals your voice December 2, 2022 Load more HOT NEWS October is National Dental Hygiene Month FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... Nivolumab: Μία σημαντική θεραπευτική επιλογή Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens...
